The loss of Humira exclusivity was long expected to be a blow to AbbVie’s immunology dominance, but the Skyrizi-Rinvoq tandem keeps outpacing expectations.
In its fourth-quarter and full-year 2024 earnings report issued Friday morning, AbbVie ...
↧